Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mushroom extract may fight smoke damage, early trial hints

NCT ID NCT07316400

Disease control Sponsor: University of Brawijaya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily supplement made from a mushroom extract (PsP) could reduce markers of oxidative stress and inflammation in 200 adults who smoke or are exposed to smoke. Participants took either PsP or a placebo for 8 weeks, and researchers measured changes in blood levels of certain chemicals linked to cell damage and inflammation. The goal is to see if this natural supplement might help protect the body from some harmful effects of cigarette smoke.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Polysaccharide peptide (PsP) from Ganoderma lucidum mushroom extract
What this could lead to
If it works, this could point toward a natural supplement to help reduce some harmful effects of smoking on the body.
What could go wrong
This is a small, early-stage trial measuring only blood markers, not health outcomes. The supplement may show no benefit or could interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Sep 2024

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female adults aged 18 to 60 years. 2. Has smoked regularly for at least the past 12 months. 3. Able and willing to provide written informed consent. 4. Agrees to maintain usual smoking habits during the study period. 5. Able to comply with study procedures and visits. Exclusion Criteria: 1. Current use of antioxidant supplements, vitamins, herbal supplements, or mushroom- derived products within the last 4 weeks. 2. Diagnosis of chronic inflammatory disease, autoimmune disease, diabetes mellitus, cardiovascular disease, chronic kidney disease, chronic liver disease, or cancer. 3. Acute illness, infection, or fever within the last 14 days. 4. Regular use of anti-inflammatory drugs (NSAIDs, corticosteroids) within the last 4 weeks. 5. Participation in another clinical study within the past 30 days. 6. Pregnant or breastfeeding. 7. Known allergy to Ganoderma lucidum or mushroom-derived compounds. 8. Alcohol dependence or substance abuse other than tobacco.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cigarette smoking are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cigarette Smoking Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cigarette smoking Inflammation Oxidative stress

Contacts and locations

Locations

  • University of Brawijaya

    Malang, East Java, 65145, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.